8-K: Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart announces BARDA approval to begin dosing in the 10,000-participant phase of its Phase 2b clinical trial for its oral COVID-19 vaccine candidate.

Summary

• Vaxart has received approval from BARDA to initiate dosing in the 10,000-participant portion of its Phase 2b clinical trial for its oral COVID-19 vaccine candidate.
• The first patient in this cohort is expected to be dosed in the second quarter of 2025.
• The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled study.
• The trial will evaluate the efficacy, safety, and immunogenicity of Vaxart's oral COVID-19 vaccine compared to an approved mRNA COVID-19 vaccine in adults previously vaccinated against COVID-19.
• Vaxart's project award through the Rapid Response Partnership Vehicle (RRPV) Consortium is valued at up to $460.7 million.
• Funding for this project comes from HHS, ASPR, and BARDA under Other Transaction (OT) number 75A50123D00005.

Sentiment

Score: 7

Explanation: The announcement is positive due to BARDA approval and significant funding, but tempered by the inherent risks and uncertainties associated with clinical trials and regulatory approvals.

Positives

• BARDA approval signifies confidence in Vaxart's oral COVID-19 vaccine candidate and its development program.
• The $460.7 million funding provides substantial resources for the Phase 2b trial and further development.
• The oral vaccine offers potential advantages over traditional vaccines, such as ease of administration and storage.

Risks

• The press release contains forward-looking statements that involve substantial risks and uncertainties.
• Clinical trial data are subject to differing interpretations and assessments by regulatory authorities.
• Vaxart's product candidates may not be approved by the FDA or non-U.S. regulatory authorities.
• Vaxart may experience manufacturing issues and delays.
• Vaxart may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection.
• Vaxart's capital resources may be inadequate.

Future Outlook

Vaxart expects to dose the first patient in the 10,000-participant cohort in the second quarter of 2025 and will continue to develop its oral vaccine platform.

Management Comments

• Steven Lo, Chief Executive Officer of Vaxart, stated that they are pleased to receive BARDA approval and expect to dose the first patient in the second quarter of 2025.
• Mr. Lo also expressed gratitude for the continued support of government partners at HHS and BARDA.

Industry Context

This announcement positions Vaxart as a key player in the development of next-generation COVID-19 vaccines, particularly oral vaccines, which could offer advantages in terms of distribution and administration compared to traditional injectable vaccines. The funding from BARDA underscores the government's commitment to supporting innovative vaccine technologies.

Comparison to Industry Standards

• Vaxart's oral vaccine approach differentiates it from companies like Pfizer and Moderna, which have focused on mRNA vaccines.
• The $460.7 million funding is substantial, but it is important to compare the Phase 2b trial design and endpoints to those of other COVID-19 vaccine trials to assess its potential impact.
• Other companies such as Novavax are also developing protein-based COVID-19 vaccines, providing alternative approaches to mRNA technology.

Stakeholder Impact

• Positive for shareholders due to the advancement of the COVID-19 vaccine program and significant funding.
• Potential benefit to the public through the development of an oral COVID-19 vaccine.
• May impact competitors in the COVID-19 vaccine market.

Next Steps

• Initiate dosing in the 10,000-participant portion of the Phase 2b clinical trial in Q2 2025.
• Evaluate the efficacy, safety, and immunogenicity of Vaxart's oral COVID-19 vaccine candidate.
• Continue development of other oral recombinant vaccines based on its proprietary delivery platform.

Key Dates

Keywords

COVID-19 vaccine, oral vaccine, Phase 2b trial, BARDA, Vaxart, VXRT, clinical trial, vaccine